Aduro Biotech ($ADRO), months removed from a $119 million IPO, is looking to settle down in Berkeley, leasing a four-story R&D complex as it presses forward with a pipeline of cancer treatments. As Berkeleyside reports, the company is planning to move into its new operation in 2016, signing a 12-year lease on a 110,000-square-foot building within the city's biomedical campus. Aduro, led by former UC Berkeley professor Stephen Isaacs, is developing a breakthrough-designated drug combination targeting pancreatic cancer, at the same time working alongside Johnson & Johnson ($JNJ) on some early stage oncology treatments. More